Agenus (AGEN)
(Delayed Data from NSDQ)
$5.09 USD
-0.19 (-3.60%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.07 -0.02 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Agenus Inc. [AGEN]
Reports for Purchase
Showing records 201 - 220 ( 260 total )
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
KOL Talks Prophage Promise in Glioblastoma; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Updated Results Highlights G-200 Efficacy in Glioblastoma - NCI to Initiate a Phase 2 Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Updated Results Highlights G-200 Efficacy in Glioblastoma - NCI to Initiate a Phase 2 Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Updated Prophage Results Prompt Large Randomized NCI Study; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Layers of Untapped Value; Initiating Coverage with a Buy Rating
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Highlights From Meeting with Management - Building an Immunotherapy Powerhouse
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Highlights From Meeting with Management - Building an Immunotherapy Powerhouse
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
From Russia with Love - New Partnership to Provide Royalties and Milestones in 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
From Russia with Love - New Partnership to Provide Royalties and Milestones in 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
3Q11 UPDATE - ROYALTY GENERATOR QS-21 VALIDATED IN PHASE 3 TRIAL
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
3Q11 UPDATE - ROYALTY GENERATOR QS-21 VALIDATED IN PHASE 3 TRIAL
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Malaria Vaccine Demonstrates Statistically Significant Results
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Malaria Vaccine Demonstrates Statistically Significant Results
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R